AbbVie to Receive Worldwide IBD Rights to Nxera Pharma Drug
Under an agreement, AbbVie will receive exclusive worldwide rights to develop and commercialize NXE0033744 for inflammatory bowel disease.
Related stories
Samsung Fire to Buy Canopius Stake With KKR, KIC
Samsung Fire & Marine Insurance is to buy the outstanding stake in Canopius with KKR and Korea Investment Corp.
M impact | MNA | Nov 09, 2026, 11:07 PM UTC
Securitize Shares Jump 11% After River One Acquisition Agreement, Revenue Beat
Securitize agreed to acquire asset-backed financing platform River One and reported third-quarter revenue above expectations. Shares rose 11% to $7.71 after hours Monday, after clo
M impact | MNA | Nov 09, 2026, 10:38 PM UTC
PharmaLogic Agrees to Buy Lantheus CDMO Business and New Jersey Facility
PharmaLogic Holdings agreed to acquire Lantheus Holdings’ contract development and manufacturing organization business and its Springfield, New Jersey, facility.
M impact | MNA | Nov 09, 2026, 10:37 PM UTC
Mayr-Melnhof Expects Cash Proceeds After Investment
Mayr-Melnhof expects cash proceeds net of an estimated investment for a stake in a new holding company.
M impact | MNA | Nov 09, 2026, 10:36 PM UTC
Forge Nano Completes Acquisition of HzO for About 7.3 Million Shares
HzO became Forge Nano’s wholly owned subsidiary. About 1.53 million of the approximately 7.3 million shares due to HzO stockholders are held back for 12 months to secure purchase-p
M impact | MNA | Nov 09, 2026, 09:43 PM UTC
Securitize Reports Third Quarter 2026 Results
Securitize also announced the River One acquisition and a $50 million share repurchase program.
M impact | MNA | Nov 09, 2026, 09:17 PM UTC